Collection and Preservation of Cord Blood for Personal Use  by unknown
Biology of Blood and Marrow Transplantation 14:364 (2008)
 2008 American Society for Blood and Marrow Transplantation
1083-8791/08/140-0001$32.00/0
doi:10.1016/j.bbmt.2007.09.011ASBMT POSITION STATEMENT
Collection and Preservation of Cord Blood for
Personal UseAmong the primary objectives of the American
Society for Blood and Marrow Transplantation
(ASBMT) are to:
● Deﬁne commonly accepted medical practices
● Develop standards of medical care for autologous
and allogeneic hematopoietic stem cell trans-
plants (HSCT)
● Provide recommendations and guidelines to both
clinicians and patients about the role of transplan-
tation as a therapeutic approach for treatment of
disease
In recent years there has been exponential growth
in the use of umbilical cord blood (UCB) as a source
of HSC for allogeneic transplant. CB that used to be
discarded as medical waste is being collected and
stored in CB banks for use when suitably matched to
a patient needing a SCT. Expectant parents today may
have the option of either donating their baby’s CB for
public use, storing the CB for personal or private use,
or discarding their newborn’s CB.
Currently, a stored unit of CB in a public bank is
at least 100 times more likely to be released for trans-
plant than a unit that is privately stored. Yet the
number of privately stored units in the United States
exceeds those in public banks by 3-fold and contin-
ues to grow. These seemingly contradictory trends
have personal, societal, and economic consequences.
To address these issues and provide advice to ex-
pectant parents, the ASBMT Board of Directors ap-
pointed a committee to review published studies and
interview experts in CB transplantation and banking.
The committee was asked to develop a report of its
ﬁndings and offer recommendations for health pro-
fessionals and for parents. The committee has com-
pleted its report, which has passed through peer re-
view for publication in Biology of Blood and Marrow
Transplantation, page 356.
The ASBMT Board of Directors also has reviewed
and accepted the report, and wishes to thank the
committee members for their careful collection of
data, analysis, and conclusions. Using the committee’s
work as a reference, the ASBMT Board of Directors364has adopted the following recommendations for
health professionals and expectant parents.
RECOMMENDATIONS
1. Expectant parents are encouraged to donate their
newborn’s UCB for public banking, when that op-
tion is available. Donation makes the CB, which is
rich in HSCs, available for life-saving treatments
when there is a suitable match with a patient.
2. Private storage of CB for future use by the new-
born is not routinely recommended. The likeli-
hood of the stored blood being used for HSCT is
very small, probably as low as 0.04% to 0.001% in
the ﬁrst 20 years of life. If later in life a transplant
is required, there likely will be superior sources of
suitable stem cells than the child’s own CB.
3. Family member banking (collecting and storing CB
for a family member) may be recommended for a
newborn who has a sibling with a disease that can
be successfully treated with HSCT. Family mem-
ber banking on behalf of a parent with a disease
that may be treated successfully with allogeneic
transplant is only recommended when there are
shared HLA-antigens between the parents.
4. Accurate and complete information about UCB
collection and banking should be available to ex-
pectant parents so that they can make informed
decisions. Parents who choose to store CB for
personal use should carefully review their contract
and ﬁnancial responsibilities, and inquire about
quality standards, median nucleated cell dose of
stored units, and accreditation of the CB bank.
5. The committee acknowledges the potential for an
expansion of indications for CB in the future, and
these recommendations will be reviewed periodi-
cally so that they remain consistent with current
medical knowledge.
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